- Skin toxicity of BRAF and MEK inhibitors2021 | First Faculty of Medicine
- Effect of target therapy with BRAF and MEK inhibitors on the immune system in metastatic melanoma2023 | First Faculty of Medicine
- Patient with abrain metastases of malignant melanoma a long-term surviving with BRAF and MEK inhibitor in combination therapy2018 | First Faculty of Medicine
- Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial2023 | First Faculty of Medicine
- Patient with lung metastases of malignant melanoma who have long-term survival in combination therapy BRAF and MEK inhibitors2019 | First Faculty of Medicine
- Long-term therapeutic response after encorafenib and binimetinib therapy - case report2023 | First Faculty of Medicine
- The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study2016 | Faculty of Medicine in Hradec Králové
- Dual targeted therapy in patients with malignant melanoma2017 | Faculty of Medicine in Hradec Králové
- Position of adjuvant therapy in the therapy of melanoma2018 | First Faculty of Medicine
- Neurological complications of cancer immunotherapy2023 | Third Faculty of Medicine
- The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies2018 | Faculty of Medicine in Hradec Králové
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma2020 | First Faculty of Medicine
- Neurofibromatosis von Recklinghausen type I (NF1) - clinical picture in childhood, diagnosis and therapy2023 | Second Faculty of Medicine
- Mechanisms of resistance in malignant melanoma treated by targeted therapy2020 | First Faculty of Medicine
- Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report2020 | Faculty of Pharmacy in Hradec Králové
- Trametinib2016 | First Faculty of Medicine
- BRAF/MED inhibitors in the treatment of malignant melanoma2018 | Third Faculty of Medicine
- Adverse Effects of Modern Treatment of Malignant Melanoma and their Treatment/Management2014 | Faculty of Medicine in Hradec Králové
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)2021 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment GO28141Publication without faculty affiliation
- Metastatic melanoma - when and how it should by treated2016 | Publication without faculty affiliation
- Complete therapeutic response to anti-PD1 therapy in patient with advanced melanoma and resistance to targeted therapy of BRAF inhibitors2018 | First Faculty of Medicine
- Cobimetinib - progress in the treatment of melanoma2017 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Advances in the treatment of metastatic melanoma2018 | First Faculty of Medicine
- A long-term survivor female patient with metastatic melanoma after treatment with pembrolizumab in the third line2020 | First Faculty of Medicine
- Long-term survival on vemurafenib monotherapy2017 | Publication without faculty affiliation
- New trends in immunotherapy of melanoma2020 | First Faculty of Medicine
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management2019 | First Faculty of Medicine
- New trends in the multiple myeloma treatment2019 | First Faculty of Medicine
- Complex treatment of melanoma2019 | First Faculty of Medicine